Predictors of glycemic and weight responses to exenatide in patients with type 2 diabetes mellitus
Predictors of glycemic and weight responses to exenatide in patients with type 2 diabetes mellitus
复制标题
DOI：
10.1007/s13410-023-01239-8
复制
发表时间：
2023-10-04
影响因子：
0.9
通讯作者：
Lv，Dongmei
中科院分区：
文献类型：
--
作者：
Huang，Yuhan;Yu，Yanan;Lv，Dongmei
目的探讨治疗后6个月内糖化血红蛋白(HbA1c)降低和体重减轻的可靠预测指标。研究中的患者被分成两组：有反应的和无反应的，根据他们在服用埃塞那肽后6个月内的血糖控制情况(有反应的人：糖化血红蛋白降低 ≥ 1.0%)和体重反应(有反应的人：体重下降 ≥ 的3%)来定义。结果148例符合纳入标准的患者中，有效者53例(35.81%)，无应答者95例(64.19%)。二元Logistic回归分析显示，基线HbA1c、基线体重和糖尿病病程是对艾塞那肽的血糖和体重反应的显著预测因子。预测患者服药后6个月内糖化血红蛋白和体重反应的ROC曲线下面积为0.765(95%可信区间：0.686~0.845)。结论基线糖化血红蛋白、基线体重和糖尿病病程可作为预测血糖和体重反应的指标。
ObjectiveThis study aimed to identify reliable predictors of haemoglobin A1c (HbA1c) reduction and weight loss within 6 months after treatment with exenatide.MethodsA total of 343 patients with type 2 diabetes mellitus were examined and followed up for 12 months. The study patients were divided into two groups: responders and non-responders, which were defined based on their glycemic control (responders: HbA1c reduction of ≥ 1.0%) and weight response (responders: weight loss of ≥ 3%) within 6 months after exenatide administration. Binary logistic regression analysis was performed to identify the predictors associated with exenatide response, and a receiver operating characteristic (ROC) curve was plotted to assess the predictive ability of the identified factors.ResultsOf the 148 patients who met the inclusion criteria, 53 (35.81%) were responders and 95 (64.19%) were non-responders. Binary logistic regression analysis revealed that baseline HbA1c, baseline weight, and duration of diabetes were significant predictors of glycemic and weight responses to exenatide. The area under the curve of the ROC for the predictors of HbA1c and weight responses within 6 months after exenatide initiation was 0.765 (95% confidence interval: 0.686–0.845).ConclusionBaseline HbA1c, baseline weight, and duration of diabetes may serve as predictors for glycemic and weight responses to exenatide.